SOURCE: MMIT Analytics, as of 3/1/19
Monday, March 4, 2019
The FDA last week approved a new...
...indication for AstraZeneca's Farxiga. The drug can now be used
in type 2 diabetes patients with moderate kidney impairment. Farxiga is found
on the preferred tier for 34% of covered lives, and is not covered for 14%. The
expanded labeling also applies to AstraZeneca's Xigduo XR.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment